Pregled bibliografske jedinice broj: 1278183
Plasma fucosylated glycans and C-reactive protein as biomarkers of HNF1A-MODY in young adult-onset nonautoimmune diabetes
Plasma fucosylated glycans and C-reactive protein as biomarkers of HNF1A-MODY in young adult-onset nonautoimmune diabetes // Diabetes care, 42 (2019), 1; 17-26 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1278183 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Plasma fucosylated glycans and C-reactive protein
as biomarkers of HNF1A-MODY in young adult-onset
nonautoimmune diabetes
Autori
Juszczak, Agata ; Pavic, Tamara ; Vuckovic, Frano ; Bennett, Amanda J. ; Shah, Neha ; Medvidovic, Edita Pape ; Groves, Christopher J. ; Sekerija, Mario ; Chandler, Kyla ; Burrows, Carla ; Putarek, Natasa Rojnic ; Lovrencic, Marijana Vucic ; Knezevic, Jadranka Cuca ; James, Tim J. ; Gloyn, Anna L. ; Lauc, Gordan ; McCarthy, Mark I. ; Owen, Katharine R. ; Gornik, Olga
Izvornik
Diabetes care (0149-5992) 42
(2019), 1;
17-26
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
plasma fucosylated glycans
Sažetak
Objective: Maturity-onset diabetes of the young (MODY) due to variants in HNF1A is the most common type of monogenic diabetes. Frequent misdiagnosis results in missed opportunity to use sulfonylureas as first-line treatment. A nongenetic biomarker could improve selection of subjects for genetic testing and increase diagnosis rates. We previously reported that plasma levels of antennary fucosylated N-glycans and high- sensitivity C-reactive protein (hs-CRP) are reduced in individuals with HNF1A-MODY. In this study, we examined the potential use of N-glycans and hs-CRP in discriminating individuals with damaging HNF1A alleles from those without HNF1A variants in an unselected population of young adults with nonautoimmune diabetes. Research design and methods: We analyzed the plasma N-glycan profile, measured hs-CRP, and sequenced HNF1A in 989 individuals with diabetes diagnosed when younger than age 45, persistent endogenous insulin production, and absence of pancreatic autoimmunity. Systematic assessment of rare HNF1A variants was performed. Results: We identified 29 individuals harboring 25 rare HNF1A alleles, of which 3 were novel, and 12 (in 16 probands) were considered pathogenic. Antennary fucosylated N-glycans and hs-CRP were able to differentiate subjects with damaging HNF1A alleles from those without rare HNF1A alleles. Glycan GP30 had a receiver operating characteristic curve area under the curve (AUC) of 0.90 (88% sensitivity, 80% specificity, cutoff 0.70%), whereas hs-CRP had an AUC of 0.83 (88% sensitivity, 69% specificity, cutoff 0.81 mg/L). Conclusions: Half of rare HNF1A sequence variants do not cause MODY. N-glycan profile and hs-CRP could both be used as tools, alone or as adjuncts to existing pathways, for identifying individuals at high risk of carrying a damaging HNF1A allele.
Izvorni jezik
Engleski
Znanstvena područja
Biologija, Temeljne medicinske znanosti
POVEZANOST RADA
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Klinička bolnica "Merkur",
GENOS d.o.o.
Profili:
Frano Vučković
(autor)
Olga Gornik Kljaić
(autor)
Mario Šekerija
(autor)
Gordan Lauc
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE